- Home
- COEP
as 11-15-2024 1:33pm EST
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | WEXFORD |
| Market Cap: | 8.1M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 282.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.15 - $1.33 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Coeptis Therapeutics Holdings Inc. News
COEP Breaking Stock News: Dive into COEP Ticker-Specific Updates for Smart Investing
PR Newswire
8 days ago
Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development
PR Newswire
22 days ago
Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
PR Newswire
a month ago
Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy
MT Newswires
2 months ago
Coeptis Therapeutics Receives Nasdaq Listing Extension
PR Newswire
2 months ago
Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
PR Newswire
2 months ago
Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders
PR Newswire
5 months ago
Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering
MT Newswires
5 months ago
--Ladenburg Downgrades Coeptis Therapeutics to Neutral From Buy
Compare COEP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COEP Coeptis Therapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.